PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
Phase 4
Completed
- Conditions
- Pancreatitis
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00318994
- Locations
- 🇨🇴
Research Site, Bogota, Colombia
Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers
Phase 2
Terminated
- Conditions
- Foot Ulcer, DiabeticDiabetes Complications
- Interventions
- Drug: Vehicle gel
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00318214
- Locations
- 🇺🇸
Associated Foot & Ankle Specialists, LLC, Phoenix, Arizona, United States
🇺🇸Innovative Medical Technologies, Los Angeles, California, United States
🇺🇸University of Miami, Miami, Florida, United States
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
Phase 2
Terminated
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00314938
- Locations
- 🇬🇧
Pfizer Investigational Site, Cardiff, United Kingdom
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
Phase 2
Completed
- Conditions
- Hot Flashes
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 527
- Registration Number
- NCT00314964
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
Phase 2
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT00313768
- Locations
- 🇺🇸
Pfizer Investigational Site, San Marcos, Texas, United States
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 204
- Registration Number
- NCT00313781
- Locations
- 🇬🇧
Pfizer Investigational Site, Guildford, United Kingdom
Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers
Phase 2
Completed
- Conditions
- Foot Ulcer, DiabeticDiabetes Complications
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 322
- Registration Number
- NCT00312364
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸UCSD Wound Treatment and Research Center, San Diego, California, United States
🇺🇸Institute for Advanced Wound Care, Montgomery, Alabama, United States
Thorough QT Study of Nelfinavir
Phase 4
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT00312182
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
Phase 3
Terminated
- Conditions
- AtherosclerosisKidney Failure
- Interventions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00311311
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency
Phase 2
Terminated
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2011-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 136
- Registration Number
- NCT00308464
- Locations
- 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath